Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing’s disease

Maria Fleseriu, Rosario Pivonello, Jacques Young, Amir H. Hamrahian, Mark E. Molitch, Chikara Shimizu, Tomoaki Tanaka, Akira Shimatsu, Tracy White, Annie Hilliard, Chuan Tian, Nicholas Sauter, Beverly M.K. Biller, Xavier Bertagna

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing’s disease'. Together they form a unique fingerprint.

Medicine & Life Sciences